Physician Private Equity Buyout: Financial Planning Guide

Private equity firms have consolidated large segments of physician medicine — dermatology, ophthalmology, orthopedics, anesthesia, gastroenterology, and increasingly primary care and hospitalist groups. If you're a physician practice owner and a PE firm has reached out, or if your group is weighing a deal, you're likely staring at the largest financial transaction of your career. The decisions you make in the 12–18 months before signing can easily be worth several hundred thousand dollars in tax savings. The decisions you make poorly — or ignore entirely — can cost you the same.

This guide explains how physician PE deals are structured, what the tax treatment looks like at each layer, why rollover equity is more complex than it appears, and what financial planning you should complete before close.

How PE physician deals are structured

PE firms cannot directly own medical practices in most states due to the corporate practice of medicine (CPOM) doctrine, which reserves clinical decision-making for licensed physicians. The standard workaround is the Management Services Organization (MSO) structure:

• The PE firm acquires or creates an MSO that handles all non-clinical operations — billing, staffing, real estate, technology, HR, and management services.
• Your physician-owned professional corporation (PC) or PLLC continues to hold the medical licenses and make clinical decisions.
• The PC signs a long-term Management Services Agreement (MSA) with the MSO, paying a management fee — often structured to capture most of the economics.
• You typically sell your equity in the PC to a new physician-owned holding entity, and separately receive cash and/or equity in the MSO parent.

The practical result: after close, you continue practicing medicine under the same roof but your practice is now embedded in a PE-backed platform targeting a larger consolidation play, regional rollup, or eventual sale to a strategic buyer or larger PE firm.

Valuations are typically expressed as a multiple of EBITDA (earnings before interest, taxes, depreciation, and amortization). Reported ranges vary widely by specialty and practice size — high-margin specialties with durable patient volume and minimal physician-specific revenue dependence tend to command higher multiples than practices where income is highly tied to one or two physicians' personal relationships.

Cash vs. rollover equity: the central tradeoff

Almost every PE deal involves a mix of cash at close and rollover equity — meaning you keep a minority stake (typically 10%–40%) in the new platform rather than cashing out entirely. PE firms require rollover equity for two reasons: it aligns your incentives with the platform's success, and it reduces the amount of capital they need to deploy.

The "second bite of the apple" is the main argument for rollover equity: if the PE platform is sold 4–5 years after your initial deal at a higher multiple, your minority stake can be worth significantly more than the cash you would have received instead. The math can be compelling — but rollover equity is a minority position in a company you don't control, and PE platform outcomes vary considerably.

Tax treatment of cash proceeds

How your cash proceeds are taxed depends on whether the deal is structured as an asset sale or a stock sale — and, within an asset sale, how the purchase price is allocated across different categories of assets.

In a typical physician practice asset sale, the purchase price is allocated across:

• Tangible assets (equipment, receivables): ordinary income or LTCG depending on asset class and depreciation recapture
• Covenant not to compete: ordinary income at up to 37%¹
• Enterprise goodwill: capital gain at long-term rates (20% + 3.8% NIIT = 23.8% for high earners in 2026)²
• Personal goodwill: see below

For a physician receiving $3M in a practice sale, the difference between having $2M allocated to ordinary income versus $2M allocated to personal goodwill (LTCG) is roughly $268,000 in federal tax. Purchase price allocation is heavily negotiated — don't leave it to whoever fills out Form 8594.

Personal goodwill: the physician tax advantage

In many medical practices, a significant portion of the economic value flows from individual physicians' skills, patient relationships, and professional reputations — not from the entity itself. Courts have recognized that this personal goodwill belongs to the individual physician, not the practice, and when sold, it is taxed at long-term capital gains rates to the physician directly.³

Personal goodwill is most defensible when:

• The physician has no employment agreement binding their future services to the entity
• The physician's expertise, referral network, or reputation is demonstrably tied to them personally
• The physician is actively willing to leave — their restraint of trade is being purchased

The personal goodwill argument is less available in large group practices where patient volume is driven by location, brand, and systems rather than individual physician identity. In a solo or small-group specialty practice, it can be substantial. The IRS scrutinizes personal goodwill claims carefully; you need a qualified M&A attorney and CPA to structure and document this correctly.

Rollover equity and §1202 QSBS after OBBBA

If your rollover equity is structured as stock in a qualifying C-corporation, it may be eligible for the §1202 Qualified Small Business Stock (QSBS) exclusion when you eventually exit — potentially shielding millions from capital gains tax entirely.

Under the One Big Beautiful Bill Act (OBBBA, signed July 2025), the §1202 exclusion was substantially enhanced for stock issued on or after July 4, 2025:⁴

For a physician with $1M in rollover equity who holds for 5+ years, the gain on exit could be fully excluded from federal capital gains — a potential savings of $238,000+ on $1M of gain at the physician income level.

QSBS eligibility requirements are strict. The issuing corporation must:

• Be a domestic C-corporation (not S-corp, LLC, or partnership)
• Have aggregate gross assets under $50M at the time of issuance (including proceeds of the issuance)
• Be an active qualified trade or business (health services qualifies; financial services does not)

Many PE platform companies exceed the $50M threshold — particularly larger platforms aggregating dozens of practices. If the PE entity has been operating for several years and has grown substantially, your rollover equity may not qualify at issuance. This is a specific question to confirm with your M&A attorney before closing, not something to discover at your eventual exit.

Earnouts: the tax trap most physicians miss

Many PE deals include earnout provisions — additional payments contingent on the practice hitting revenue or EBITDA targets in the 1–3 years post-close. Earnouts bridge valuation gaps between what the PE firm is willing to pay today versus what physicians believe the practice will produce.

The tax treatment of earnouts is unfavorable and frequently misunderstood:

• If earnout payments are structured as purchase price contingent on business performance, they are generally taxed as capital gains — the better outcome.
• If earnout payments are tied to your continued employment or personal production metrics, the IRS typically treats them as ordinary compensation income — subject to the 37% top rate plus payroll taxes, not LTCG rates.

PE deal documents often tie earnout targets to metrics that are effectively physician productivity measures. The closer the payment tracks your personal effort rather than enterprise performance, the harder it is to defend LTCG treatment. This is another negotiating point that has six-figure implications and needs a transactional tax attorney before you sign.

Pre-close planning moves

The most valuable tax planning happens before close — not after you've already signed and the purchase price structure is locked.

Maximize retirement contributions before close

If your practice has a solo 401(k) or cash balance plan, max contributions for the final year before the plan terminates. A solo 401(k) allows up to $72,000 combined employee deferral + employer profit sharing in 2026.⁵ A cash balance plan can shelter $100,000–$300,000+ depending on your age (the §415(b) limit is $275,000 for 2026). These pre-tax contributions reduce your taxable income in what may be a very high-income year.

Note: defined benefit / cash balance plan termination after a sale requires IRS compliance steps — including filing for a determination letter and the §4980 excise tax trap if plan assets exceed the maximum distributable amount. Plan for this with a benefits attorney or CPA.

Roth conversion window

If your income will spike in the sale year, consider Roth conversions in the 1–2 years before close when income may still be at normal physician levels. Once the deal closes, you lose that conversion window at current rates and face potentially higher marginal income in the sale year and the years immediately after (employment income + investment income from proceeds).

Installment sale timing

Under §453, you may be able to spread cash proceeds over multiple tax years via an installment sale — especially useful if the sale year would otherwise push you into an even higher bracket. PE deals don't always accommodate installment sales, but it's worth modeling with your CPA if you're near bracket thresholds.

Post-close: employment, compensation, and investing

After close, you're an employee of the PE platform. Key financial dimensions:

Employment compensation: Your compensation post-close is typically a mix of base salary and productivity-based bonuses. Your negotiating leverage disappears after you've signed — understand the compensation model, wRVU benchmarks, and bonus targets before you commit. See the wRVU compensation calculator for benchmarks.

Benefits gap: As a W-2 employee of the MSO, you lose practice-owner benefits: solo 401(k) eligibility, the ability to elect S-corp status for side income, and the flexibility to deduct practice expenses through your own entity. You gain the retirement plan the MSO provides (which may or may not be as generous as your prior self-directed plan).

Post-close investing: A lump-sum cash payout creates a classic dollar-cost averaging vs. lump-sum investment decision. Research consistently shows lump-sum investing outperforms DCA roughly two-thirds of the time for equity-heavy portfolios, but the behavioral reality for a physician suddenly holding $3M in cash is different. A fee-only advisor can model the specific numbers for your situation. See the physician investment portfolio guide for account sequencing and allocation framework.

Red flags to watch in PE deals

• Aggressive non-competes: Broad geography, long duration, or specialty-specific restrictions can end your career in your community if the deal goes badly. Non-compete scope is heavily negotiated and varies dramatically by state enforceability.
• Earnout targets that are effectively productivity requirements: If meeting your earnout requires you to see X patients per day indefinitely, you've essentially agreed to a work rate floor with no mechanism to reduce it.
• No liquidity path for rollover equity: Confirm what happens to your equity if the PE firm doesn't pursue a secondary transaction on the timeline you expect. Ask about tag-along rights, drag-along provisions, and put options.
• Employment compensation below market: PE firms sometimes front-load the purchase price and reduce post-close compensation, making total economics worse than staying independent. Model the full 5–7 year economic picture including salary, bonus, and expected rollover equity value — not just the check at close.
• Verbal assurances about clinical autonomy: Clinical autonomy commitments that aren't in the contract don't exist. If preserving control over your clinical decisions matters to you, it needs to be in writing.